AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02519465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
Study NCT02519465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50l/min
Description: For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
Study NCT01761864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: academic detailing intervention
Study NCT01514331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)
Description: Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
Study NCT01514331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV+VG (pressure support ventilation+volume guarantee)
Description: Neonates who need mechanical ventilation will be ventilated with PSV+VG
Study NCT02850354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-g maneuvers
Description: investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: YH4808 400mg (single dose)
Study NCT02608203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-DOTANOC PET/CT
Study NCT00469651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP 3 Long Synthetic Peptide
Description: Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
Study NCT00469651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 vaccine
Description: Lyophilized vaccine adjuvanted in Aluminium hydroxide
Study NCT00469651 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine adjuvanted in Aluminium hydroxide
Study NCT01631903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 6 mg
Description: 6 mg, vaginal capsule, once daily for 3 months
Study NCT01631903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 12 mg
Description: 12 mg, vaginal capsule, once daily, for 3 months
Study NCT01631903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telepristone acetate 24 mg
Description: 24 mg, vaginal capsule, once daily for 4 months
Study NCT01355068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanutin Infatabs (Phenytoin)
Description: Chewable Tablet, 50 mg, Single dose
Study NCT01355068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilantin Infatabs (Phenytoin)
Description: Chewable Tablet, 50 mg, Single dose
Study NCT03207022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary brachial plexus block
Description: ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
Study NCT03207022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary brachial plexus block
Description: ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
Study NCT04969016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSA (liquid skin adhesive)
Description: surgical wound closure with liquid skin adhesive (LiquiBand®)
Study NCT04969016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapler
Description: surgical wound closure with stapler
Study NCT02236546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose
Description: FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
Study NCT02236546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular assays on biopsied tissue
Description: Correlative studies
Study NCT02236546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT
Study NCT02236546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
Study NCT03778177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial electrical brain stimulation
Description: Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
Study NCT04212494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Percutaneous Coronary Intervention with manual aspiration thrombectomy
Study NCT04212494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI Alone
Description: Percutaneous Coronary Intervention without manual aspiration thrombectomy
Study NCT04032470 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation Systems (DBS)
Description: Subjects receiving DBS implant for treatment of Essential Tremor
Study NCT00469651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 candidate vaccine
Description: Lyophilized MSP3 adjuvanted in Aluminium hydroxide
Study NCT00469651 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B control vaccine
Description: Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
Study NCT00619593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified diagnostic and treatment measures following 1st appropriate ICD therapy
Description: * Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication
Study NCT00619593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard follow-up in patients without appropriate ICD therapy
Study NCT02145585 — intervention group
Intervention type: DEVICE
Intervention: Test of pharmacologic anesthesia robot (labVIEW® software)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100mg (repeat dose)
Description: YH4808 100mg (repeat dose)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 200mg (repeat dose)
Description: YH4808 200mg (repeat dose)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 600mg
Description: YH4808 600mg
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 800mg (single dose)
Description: YH4808 800mg (single dose)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 400 mg (repeat doses)
Description: YH4808 400 mg (repeat doses)
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 volunteers will be administered matched placebo.
Study NCT01007019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: 24 volunteers will be administered Esomeprazole 40mg
Study NCT02299687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT03264664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: Oral immediate release tablets.
Study NCT03712202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given IV
Study NCT03712202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03712202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study NCT03712202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03712202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03712202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03712202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study NCT01783054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
Study NCT01783054 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Expression
Description: Subjects will have genetic expression testing done on their tissue samples.
Study NCT01783054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
Study NCT02457546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL Fibrin Sealant
Study NCT02457546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel sealant
Study NCT01881958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277®
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ham
Description: 160g per day during 4 days
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ham + pomegranate extract
Description: 160g per day during 4 days
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ham + tocopherol
Description: 160g per day during 4 days
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rare sirloin steak
Description: 110g per day during 4 days
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: marinated rare sirloin steak
Description: 110g per day during 4 days
Study NCT02473302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: marinated cooked sirloin steak
Description: 110g per day during 4 days
Study NCT03348462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethosomal preparation of anthralin
Description: once daily with short contact topical application
Study NCT03348462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal preparation of anthralin
Description: once daily with short contact topical application
Study NCT01945112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paper Tape
Description: Applied to blister prone areas of the foot
Study NCT02056145 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Normal Saline solution 10 cc
Study NCT02056145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Normal Saline solution 10 cc
Study NCT02056145 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FNB
Description: FNB - Normal saline solution 10 cc
Study NCT02056145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LFCNB
Description: LFCNB - Chirocaine 0.25%, 20 cc
Study NCT02056145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB
Description: FNB - Chirocaine 0.25%, 20 cc
Study NCT03757338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod Reference Formulation
Description: To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
Study NCT03757338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod Test Formulation
Description: To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
Study NCT02670434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK-104-CR
Description: NK-104-CR 8 mg daily for 52 weeks
Study NCT02670434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 12 weeks
Study NCT02670434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo
Description: Livalo® IR daily from week 12 to week 52
Study NCT05843955 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
Study NCT03267251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vacteens Web app for mobile devices
Description: The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
Study NCT03267251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Usual and Customary HPV Information - CDC pamphlet
Description: The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
Study NCT01710046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CP-6890,550) Tofacitinib
Description: 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Study NCT03266055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g of blueberry powder, taken daily for 8 weeks
Description: Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
Study NCT03266055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50g of placebo blueberry powder, taken daily for 8 weeks
Description: Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
Study NCT04678063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to Placebo
Description: Patients are exposed to placebo in the EEC
Study NCT04678063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to Placebo
Description: Patients are exposed to placebo in the EEC
Study NCT04678063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to dose A and dose B of cat allergen
Description: Patients are exposed to dose A and B for successive exposures in the EEC
Study NCT04678063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to a single dose of cat allergen
Description: Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
Study NCT03433703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)
Study NCT01659034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine for 3 months
Study NCT03690089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
Study NCT03690089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
Study NCT04459676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) + ANG-3777
Description: Standard of Care (SOC) + ANG-3777
Study NCT04459676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Of Care (SOC) + Placebo
Description: Standard Of Care + Placebo
Study NCT01872000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Study NCT01872000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Study NCT01013337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Study NCT01013337 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Placebo acupuncture
Study NCT02163863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoropopliteal stenting
Study NCT02163863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoropopliteal stenting
Study NCT02985138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLIF and unilateral pedicle screw fixation
Description: TLIF combined with posterior unilateral pedicle screw fixation
Study NCT02985138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLIF and bilateral pedicle screw fixation
Description: TLIF combined with posterior bilateral pedicle screw fixation
Study NCT02985138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screw and cage
Description: Pedicle screw and cage
Study NCT02985138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle screw and cage
Description: Pedicle screw and cage
Study NCT04053426 — intervention group
Intervention type: OTHER
Intervention: Implementation of agitation care algorithm
Description: Following the agitation care algorithm care professional adapt their behavior regarding agitation
Study NCT02455726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Description: Oral magnesium oxide 300 mg twice a day
Study NCT02455726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructose
Description: Oral fructose 10 g twice a day
Study NCT01710046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Study NCT01710046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CP-690,550) Tofacitinib
Description: 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
Study NCT02455726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone hydrochloride 5 mg at 8 am
Study NCT02455726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone hydrochloride 5 mg at 8 am
Study NCT02455726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 25 mg at 8 pm
Study NCT02455726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25 mg at 8 pm
Study NCT00975325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: yohimbine 5 mg, one tablet, single dose only
Study NCT00952042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training
Description: Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
Study NCT00952042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric resistance training
Description: Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
Study NCT01975051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitefosine
Description: Tablet Miltefosine 100 mg in two devided doses for 12 weeks
Study NCT00467857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: InteguSeal* skin sealant and standard surgical preparation
Description: Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
Study NCT00467857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard preoperative skin preparation
Description: Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.